{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone+5mg+Tab", "query": { "intervention": "Prednisone 5mg Tab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone+5mg+Tab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T22:10:37.680Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06136624", "title": "Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Opevesostat", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Fludrocortisone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1310, "start_date": "2023-12-31", "completion_date": "2030-02-15", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-03T22:10:37.680Z", "location_count": 48, "location_summary": "Orange, California • Palo Alto, California • Riverside, California + 41 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Highlands Ranch", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06136624" }, { "nct_id": "NCT04691804", "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "Fuzuloparib , Abiraterone acetate and Prednisone", "type": "DRUG" }, { "name": "Fuzuloparib Placebo， Abiraterone acetate and Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jiangsu HengRui Medicine Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 496, "start_date": "2021-03-18", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-09-03T22:10:37.680Z", "location_count": 17, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04691804" }, { "nct_id": "NCT00608894", "title": "LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autoimmune Hepatitis" ], "interventions": [ { "name": "LCP-Tacro (tacrolimus)", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veloxis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2007-12", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2020-03-17", "last_synced_at": "2026-09-03T22:10:37.680Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00608894" }, { "nct_id": "NCT05867329", "title": "Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ulcerative Colitis Acute" ], "interventions": [ { "name": "Cyclosporine Injection (IV)", "type": "DRUG" }, { "name": "Cyclosporine Oral Product", "type": "DRUG" }, { "name": "Upadacitinib Extended Release Oral Tablet", "type": "DRUG" }, { "name": "Intravenous Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone Oral Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Berinstein, Jeffrey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 700, "start_date": "2023-09-30", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-03T22:10:37.680Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867329" }, { "nct_id": "NCT00110669", "title": "High-dose Prednisone in Duchenne Muscular Dystrophy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cooperative International Neuromuscular Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "10 Years", "sex": "MALE", "summary": "4 Years to 10 Years · Male only" }, "enrollment_count": 64, "start_date": "2004-01", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2011-10-27", "last_synced_at": "2026-09-03T22:10:37.680Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110669" }, { "nct_id": "NCT00596947", "title": "Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Transplants and Implants" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "rabbit antithymocyte globulin", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "19 Years to 74 Years" }, "enrollment_count": 18, "start_date": "2005-10", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-09-03T22:10:37.680Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00596947" }, { "nct_id": "NCT04291664", "title": "PK and Dose Escalation and Expansion Study of DST-2970", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone 5Mg Tab", "type": "DRUG" }, { "name": "DST-2970 (Abiraterone)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DisperSol Technologies, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 26, "start_date": "2020-01-31", "completion_date": "2023-01-27", "has_results": false, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-09-03T22:10:37.680Z", "location_count": 5, "location_summary": "Miami, Florida • New Orleans, Louisiana • New York, New York + 2 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" }, { "city": "Myrtle Beach", "state": "South Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04291664" }, { "nct_id": "NCT03793439", "title": "Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoidosis, Pulmonary", "Sarcoidosis Lung", "Sarcoidosis" ], "interventions": [ { "name": "Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial", "type": "DRUG" }, { "name": "Spirometry", "type": "DIAGNOSTIC_TEST" }, { "name": "RNA Sequencing", "type": "GENETIC" }, { "name": "Laboratory testing", "type": "DIAGNOSTIC_TEST" }, { "name": "Corticosteroid", "type": "DRUG" }, { "name": "Tofacitinib 5mg [Xeljanz] 1 year open-label extension", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "GENETIC" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 5, "start_date": "2019-05-15", "completion_date": "2021-06-24", "has_results": true, "last_update_posted_date": "2022-02-18", "last_synced_at": "2026-09-03T22:10:37.680Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03793439" }, { "nct_id": "NCT05593497", "title": "A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High-Risk Prostate Cancer" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2024-05-31", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-03T22:10:37.680Z", "location_count": 9, "location_summary": "West Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 6 more", "locations": [ { "city": "West Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "The Bronx", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05593497" }, { "nct_id": "NCT04060394", "title": "Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Phase I and Phase II: LAE001/prednisone + afuresertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Laekna Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 49, "start_date": "2019-09-13", "completion_date": "2024-03-30", "has_results": false, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-09-03T22:10:37.680Z", "location_count": 12, "location_summary": "Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04060394" } ] }